Target intelligence / Profile preview

Other fibronectin-binding integrins

Molecular classification
Receptor, Integrin family, Heterodimeric cell surface receptor
01

Overview

Other fibronectin-binding integrins refers to a diverse group of heterodimeric cell surface receptors, excluding the primary fibronectin receptor alpha-5-beta-1, that mediate cellular interactions with the extracellular matrix protein fibronectin (NIH, PubMed). This group primarily includes members of the alpha-v subfamily (alpha-v-beta-1, alpha-v-beta-3, alpha-v-beta-5, alpha-v-beta-6, and alpha-v-beta-8) as well as alpha-4-beta-1, alpha-8-beta-1, alpha-9-beta-1, and the platelet-specific alpha-IIb-beta-3 (NIH, Reactome). These receptors typically recognize the Arg-Gly-Asp (RGD) tripeptide motif or the Leu-Asp-Val (LDV) motif within fibronectin to regulate essential processes like cell adhesion, migration, and survival (Wikipedia, NIH). In pathological contexts, these integrins are heavily implicated in tumor angiogenesis, cancer metastasis, and the activation of latent TGF-beta, which drives tissue fibrosis (Frontiers, PubMed). Consequently, they have been the focus of numerous therapeutic strategies, including monoclonal antibodies and small-molecule antagonists, aimed at treating oncology, inflammatory diseases, and fibrotic disorders (NIH, PubMed).

Other names
Non-alpha5beta1 fibronectin receptorsRGD-binding integrinsAlpha-v integrin familyAlpha4beta1 (VLA-4)Alpha8beta1Alpha9beta1AlphaIIbbeta3 (Platelet glycoprotein IIb/IIIa)
02

Mechanism of action

Competitive antagonism of the ligand-binding pocket (specifically the RGD or LDV recognition sites), which prevents the integrin from interacting with fibronectin and other extracellular matrix proteins, thereby blocking adhesion-dependent signaling and the mechanical activation of latent TGF-beta (NIH, PubMed).

03

Biological functions

Cell adhesionCell migrationSignal transductionAngiogenesisTGF-beta activationWound healingExtracellular matrix assembly
04

Disease associations

CancerFibrosisInflammationThrombosisCardiovascular diseaseOsteoporosis
05

Safety considerations

Risk of Progressive Multifocal Leukoencephalopathy (PML) with alpha-4-beta-1 inhibition (NIH)Increased bleeding risk with alpha-IIb-beta-3 inhibition (Wikipedia)Potential for paradoxical integrin activation at sub-therapeutic doses (Frontiers)Lack of clinical efficacy in some oncology trials due to redundancy or compensation (NIH)
06

Interacting drugs

Cilengitide

8 more in the full profile.

07

Biomarkers

Integrin alpha-v-beta-3 expressionIntegrin alpha-v-beta-6 expressionPlasma TGF-beta levelsFibronectin splice variants (e.g., ED-B)

Beyond the preview

Go deeper on Other fibronectin-binding integrins.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Other fibronectin-binding integrins.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call